Objective: To study the association between hormonal exposures and disease onset in a cohort of women with neuromyelitis optica spectrum disorder (NMOSD).
Neuromyelitis optica (NMO) is a severe inflammatory neurologic disease, whose main clinical manifestations are simultaneous or successive episodes of optic neuritis and transverse myelitis. NMO is associated with serum immunoglobulin G antibodies to aquaporin-4, which are present in about 75% of patients with NMO. "NMO-spectrum disorders" (NMOSDs) is a unifying term to describe the clinical spectrum of NMO, including aquaporin-4 antibody-positive patients with limited forms of the disease. The female-to-male ratio in NMOSD is up to 9:1, 1,2 but the role of sex-specific hormones in disease pathogenesis has not been explored.
In MS, another CNS demyelinating disease with high female:male ratio (2-3:1 and possibly increasing 3, 4 ), earlier age at menarche is associated with earlier age at MS onset. Pregnancy reduces the risk of an MS relapse, 5, 6 and increasing parity is associated with lower risk of long-term disease progression. 7 In NMOSD, the risk of relapses and of first disease onset is increased during the pregnancy and postpartum periods relative to baseline. [8] [9] [10] [11] In this cohort study, we hypothesized that, as seen in MS, both exogenous and endogenous hormonal exposures are associated with age at NMOSD onset. First, we describe the reproductive exposures of an international multicenter cohort of women with NMOSD; second, we examine the association between these hormonal exposures and age at disease onset. Standard protocol approvals, registrations, and patient consents. Informed consent was obtained from all participants under institutional review board policies at each site.
Participants. A total of 217 women who met current published diagnostic criteria for NMOSD with or without aquaporin-4 antibodies 12 were enrolled consecutively, and all participants completed at least 1 component of the questionnaire.
Questionnaire. The reproductive survey included questions about menarche, pregnancies, menopause, and exogenous hormones. 13 It was conducted using REDCap, a secure Health Insurance Portability and Accountability Act compliant web-based survey tool. This questionnaire had previously good concordance of selected variables against the medical record in women with MS.
14 For this study, the following variables were examined: , p 5 0.68). With respect to hormonal exposures, the mean age at menarche was 12.8 years (SD 1.7), and 61% of women reported systemic oral HC use for at least 12-month duration. The median number of total pregnancies was 2 (SD 1.6) and occurring after NMOSD FS was 0 (SD 0.7). Thirteen percentage of respondents (26/193) reported delay in achieving pregnancy of 12 months or longer, and in the 11 in whom a reason for their infertility was identified, the causes were as follows: ovarian cysts (n 5 3), structural problems (n 5 3, including 1 endometriosis), hormonal dysregulation (n 5 3), and male factors (n 5 2). Twelve participants (6%) reported receiving infertility treatment.
Among the 117 postmenopausal participants, 70% (n 5 82) reported natural menopause (mean age: 48.9 years [SD 3.9]); only 25% (n 5 29) reported systemic HT use. Given prior reports that women with neurologic disabilities may access fewer components of general health promotion (such as cancer screening, 16 or HT, which was often "standard of care" during the epoch corresponding to this cohort's menopausal transition 17 ), we compared HT use in postmenopausal participants with FS occurring before vs after their final menstrual period. Women with FS after their menopause reported greater HT use (37%) than women with FS prior to menopause (16%; x 2 test 5 5.68, p 5 0.016). Association between reproductive exposures and age at disease onset is summarized in table 2:
Menarche. Ten participants (4.6%) reported FS prior to age of 18, 7 of whom reported FS within 2 years prior to (n 5 2) or after (n 5 5) menarche. There was no association between FS age and menarcheal age (linear regression, estimate 5 0.91, p 5 0.12).
HC use. Ever-use of systemic HC was associated with earlier FS (39.3 vs 43.4 years), but this was marginally significant (linear regression, estimate 5 2.1, p 5 0.05; figure).
Parity. A later FS was also associated with a greater number of preceding pregnancies (estimate 5 3.3, p , 0.0001). Because participant age confounded In sensitivity analyses, the significance of the findings reported was unchanged when we included race, ethnicity, and NMO antibody positivity as covariates in the models. DISCUSSION This study, conducted in a large international survey of women with NMOSD, represents a preliminary analysis of the relationship from NMOSD onset to hormonal factors beyond pregnancy. With respect to endogenous exposures, unlike in MS, we saw no association between menarcheal age and NMOSD onset. [18] [19] [20] [21] As in other cohorts, 5% of our participants reported FS before the age of 18.
2,22
The association between a greater number of preceding pregnancies and later NMOSD FS (p , 0.0001) was expected, as parity increases with age. Future studies should examine the association between age at first offspring's birth (not available in our cohort) and FS age. It is important that the number of pregnancies after disease onset was far outnumbered by those prior to disease onset. While this may partly reflect the older age of women at FS, it may also reflect reproductive choices relating to uncertainty of disease course, need for new medications that have uncertain effects on a fetus, and concerns about the future ability to care for a child, as has been reported in MS. 23 Inclusion of NMO antibody positivity in the sensitivity analyses did not change the significance (or nonsignificance) of the relationship between endogenous hormonal exposures and FS age. In a separate manuscript, we describe the association between pregnancy and relapses in this cohort (Klawiter, personal communication) . It is notable that 6% of the respondents reported use of fertility treatments. Larger case-control studies adjusting for participant age are needed to determine whether there is an association between NMOSD and infertility.
With respect to exogenous exposures, we observed a marginally significant association between ever-use of HC and earlier age at NMOSD onset. From a broader perspective, evidence for an association between HC and autoimmune diseases is mixed (including lower, [24] [25] [26] neutral, 27,28 and higher 29 risk of MS) and likely is confounded by changing HC formulations across epochs. Furthermore, the confounding effect of delayed (or no) childbearing that is achieved through HC use has not been adequately assessed, nor has the effect of participant age on recall of HC use. Follow-up studies are required to confirm this association, and, if this is confirmed, to assess HC dosing effects and whether the association is causative.
Approximately, one-quarter of all participants reported a postmenopausal onset of FS, which contrasts with MS, where fewer than 10% develop MS FS after the age of 50. 30 The detection rate of serum aquaporin-4 autoantibodies has been reported to increase in women relative to men particularly after the age of 50, suggesting an effect of reproductive immunosenescence on NMOSD features. 22 We observed no relationship between FS age and reported NMO antibody positivity.
The primary strengths of this multicenter study include an international design with a relatively large sample size, the use of specific diagnostic criteria for NMOSD, and the use of a standardized fairly comprehensive reproductive survey. Still, numbers were overall low, participants were mostly Caucasians from European and North American centers, possibly limiting generalizability of findings, occasionally data were missing, and reliance on patient-reported hormonal exposures may have introduced recall bias. In addition, we were not adequately powered to detect epochal factors potentially associated with both exogenous hormone use and NMOSD susceptibility or disease course, or to detect differences across clinical centers. We also identified further refinements needed to the reproductive survey (e.g., age at first birth and HC formulations).
While we selected age at NMOSD as our initial clinical measure of interest, further studies should evaluate the association between endogenous and exogenous hormonal exposures and other NMOSD characteristics of interest, including clinical severity and progression, and severity of inflammation on MRI.
Studies that include detailed hormonal analysis and immunopathogenetic measures are required to replicate these results and further elucidate the role of endogenous and exogenous hormonal exposures on this female predominant autoimmune disease, as well as important pathophysiologic implications. Age at NMOSD first symptom onset in women with and without prior exposure to systemic hormonal contraceptives NMOSD 5 neuromyelitis optica spectrum disorder.
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